Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
B-cell lymphoma marginal zone
MeSH D018442 - b-cell lymphoma marginal zone
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D016393:
B-cell lymphoma
15 Companies
7 Drugs
$
Success rate
D018442:
B-cell lymphoma marginal zone
1 Company
1 Drug
$
Success rate
Events Timeline
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TG Therapeutics
Umbralisib
Ukoniq
2033-07-02
2021-02-05
Clinical Trials
Historical Success Rate
Phase 1
65
%
46/71
Phase 2
3
%
2/80
Phase 3
29
%
2/7
Approved:
2
Overall Success rate:
0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
TG Therapeutics
Umbralisib
,
Doconexent
,
Cc5013
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use